The Indian Journal of Pediatrics

, Volume 85, Issue 4, pp 261–265 | Cite as

Effects of Growth Hormone Treatment on Lipid Profiles

  • Toshihide KuboEmail author
  • Mahoko Furujo
  • Kyohei Takahashi
  • Yuki Hyodo
  • Hiroki Tsuchiya
  • Mariko Hattori
  • Shoko Fujinaga
  • Kenji Urayama
Original Article



To assess the effects of growth hormone (GH) on lipid profiles in children and whether the effect is pharmacological.


The authors determined serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and low-density lipoprotein cholesterol (LDL-C) every year during 3-y GH treatment in 48 GH deficient (GHD) short children and 22 children with short stature born small for gestational age (SGA).


The abnormally high levels of TC, non-HDL-C, and LDL-C showed a high frequency in GHD short children compared with epidemiological studies in Japan. The high prevalence of high level of TC was also shown in SGA short children. Three-year GH treatment decreased serum TC, non-HDL-C, and LDL-C levels in both patient groups.


GH treatment is clearly a pharmacological therapy in SGA short children and so may also be in GHD short children at the Japanese standard therapeutic dose. Taken together, GH improves lipid profiles, and its effect has the possibility of medical properties.


Growth hormone Lipid Cholesterol Growth hormone deficiency Small for gestational age 



TK designed this study; KT analyzed the data, and the other authors acquired the data; TK drafted the manuscript, and the other authors revised it. All authors have read and approved the final manuscript. TK will act as guarantor for the paper.

Compliance with Ethical Standards

Ethics Committee Approval

This study was approved by the ethics committee of the National Hospital Organization, Okayama Medical Center. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments.

Conflict of Interest


Source of Funding

Supported by National Hospital Organization, Okayama Medical Center.


  1. 1.
    Itoh E, Hizuka N, Fukuda I, Takano K. Metabolic disorders in adult growth hormone deficiency; a study of 110 patients at a single institute in Japan. Endocr J. 2006;53:539–45.CrossRefPubMedGoogle Scholar
  2. 2.
    Claessen KM, Appleman-Dijkstra NM, Adoptie DMMM, et al. Metabolic profile in growth horomone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy. J Clin Endocrinol Metab. 2013;98:352–61.CrossRefPubMedGoogle Scholar
  3. 3.
    Gazzaruso C, Gola M, Karamouzis I, Giubbini R, Giustina A. Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH-an update. J Clin Endocrinol Metab. 2014;99:18–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Fukuda I, Hizuka N, Muraoka T, Ichihara A. Adult growth hormone deficiency: current concepts. Neurol Med Chir (Tokyo). 2014;54:599–605.CrossRefGoogle Scholar
  5. 5.
    Uzunova I, Kirilov G, Zacharieva S, Shinkov A, Borissova A-M, Klinov K. Individual risk factors of the metabolic syndrome in adult patients with growth hormone deficiency-a cross-sectional case-control study. Exp Clin Endocrinol Diabetes. 2015;123:39–43.PubMedGoogle Scholar
  6. 6.
    Chihara K, Koledova E, Shimatus A, et al. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency. Eur J Endocrinol. 2005;153:57–65.Google Scholar
  7. 7.
    Lanes R, Gunczler P, Lopez E, Esaa S, Villaroel O, Revel-Chion R. Cardiac mass and function, carotid artery intima-media thickness, and lipoprotein levels in growth hormone-deficient adolescents. J Clin Endocrinol Metab. 2001;86:1061–5.CrossRefPubMedGoogle Scholar
  8. 8.
    van der Sluis IM, Boot AM, Hop WC, de Rijke YB, Krenning EP, de Muinck K-SSMPF. Long-term effects of growthhormone therapy on bone mineral density, body composition, and serum lipid levels in growth hormone deficeient children: a 9-year follow-up study. Horm Res. 2002;58:207–14.PubMedGoogle Scholar
  9. 9.
    Salerno M, Esposito V, Spinelli L, et al. Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy. Clin Endocrinol. 2004;60:630–6.CrossRefGoogle Scholar
  10. 10.
    Ciresi A, Amatto MC, Criscimanna A, et al. Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol. 2007;156:353–60.CrossRefPubMedGoogle Scholar
  11. 11.
    Meazza C, Elsedfy HH, Pagani S, Bozzola E, El Kholy M, Bozzola M. Metabolic parameters and adipokine profile in growth hormone deficient (GHD) children before and after 12-month GH treatment. Horm Metab Res. 2014;46:219–23.PubMedGoogle Scholar
  12. 12.
    Foster C, Burton A, Scholl J, Scott ML, Gunter V, McCormick K. Lipid patterns in treated growth hormone deficient children vs. short stature controls. J Pediatr Endocri Met. 2014;27:909–14.Google Scholar
  13. 13.
    Kuromaru R, Kohno H, Ueyama N, Hassan HMS, Honda S, Hara T. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabokic effects. J Clin Endocrinol Metab. 1998;83:3890–6.PubMedGoogle Scholar
  14. 14.
    Tenhola S, Martikainen A, Rahiala E, Herrgård E, Halonen P, Voutilainen R. Serum lipid concentrations and growth characteristics in 12-year-old children born small for gestational age. Pediatr Res. 2000;48:623–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Ogden C, Schoendorf KC, Kiely JL, Gillman MW. Fetal growth and childhood cholesterol levels in the United States. Pediatr Perinat Epidemiol. 2008;22:5–11.CrossRefGoogle Scholar
  16. 16.
    Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab. 2000;85:3786–92.PubMedGoogle Scholar
  17. 17.
    van Dijk M, Bannink EMN, van Pareren YK, Muldre PGH, Hokken-Koelega ACS. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls. J Clin Endocrinol Metab. 2007;92:160–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Kappelgaard AM, Kiyomi F, Horikawa R, Yokoya S, Tanaka T. The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age. Horm Res Paediatr. 2014;81:272–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Tanaka T, Yokoya S, Seino Y, et al. Long-term efficacy and safety of two doses of growth hormone in short Japanese children born small for gestational age. Horm Res Paediatr. 2011;76:411–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Tanaka T, Tachibana K, Shimatsu A, et al. A nationwide attempt to standardize growth hormone assays. Horm Res. 2005;64:6–11.PubMedGoogle Scholar
  21. 21.
    Approved Guideline - Evaluation of precision performance of clinical chemistry devices, EP5-A. 1999. National Committee for Clinical Laboratory StandardsGoogle Scholar
  22. 22.
    Müller A, Scholz M, Blankenstein O, et al. Harmonization of growth hormone measurements with different immunoassays by data adjustment. Clin Chem Lab Med. 2011;49:1135–42.CrossRefPubMedGoogle Scholar
  23. 23.
    Katsumata N, Shimatsu A, Tachibana K, et al. Continuing efforts to standardize measured serum growth hormone values in Japan. Endocr J. 2016;63:933–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Kubo T, Takahashi K, Furujo M, et al. Usefulness of non-fasting lipid parameters in children. J Pediatr Endocrinol Met. 2017;30:77–83.Google Scholar
  25. 25.
    Asayama K, Ozeki T, Sugihara S, et al. Criteria for medical intervention in obese children: a new definition of ‘obesity disease’ in Japanese children. Pediatric Int. 2003;45:642–6.CrossRefGoogle Scholar
  26. 26.
    Okada T, Murata M, Yamaguchi K, Harada K. New criteria of normal serum lipid levels in Japanese children: the nationwide study. Pediatr Int. 2002;44:596–601.CrossRefPubMedGoogle Scholar
  27. 27.
    Abe Y, Okada T, Sugiura R, Yamauchi K, Murata M. Reference ranges for the non-high-density lipoprotein cholesterol levels in Japanese children and adolescents. J Atheroscler Thromb. 2015;22:669–75.CrossRefPubMedGoogle Scholar
  28. 28.
    Lind S, Rudling M, Ericsson S, Olivecrona H, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol. 2004;24:349–56.CrossRefPubMedGoogle Scholar
  29. 29.
    Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activates in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. 2000;153:491–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Tell GS, Mittelmark MB, Vellar OD. Cholesterol, high density lipoprotein cholesterol and triglycerides during puberty: the Oslo Youth study. Am J Epidemiol. 1985;122:750–61.CrossRefPubMedGoogle Scholar
  31. 31.
    Finkelstein JW, Roffwarg HP, Boyard RM, Kream J, Hellman L. Age-related changes in the twenty-four-hour spontaneous secretion of growth hormone. J Clin Endocrinol Metab. 1972;35:665–70.Google Scholar
  32. 32.
    Martha PM Jr, Gorman KM, Blizzard RM, Rogol AD, Veldhuis JD. Endogenous growth hormone secretion and clearance rates in normal boys, as determined by deconvolution analysis: relationship to age, pubertal status, and body mass. J Clin Endocrinol Metab. 1992;74:336–44.PubMedGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  1. 1.Department of PediatricsNational Hospital Organization, Okayama Medical CenterOkayamaJapan

Personalised recommendations